

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patentee: Cockerill *et al.*

Patent No.: 6,933,299

Issued: August 23, 2005

Serial No.: 10/030,527

For: ANILINOQUINAZOLINES AS PROTEIN KINASE INHIBITORS

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 CFR § 1.322

Mail Stop Post Issue
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed please find a certificate of correction in connection with the above-identified patent. It is respectfully requested that a Certificate of Correction be issued for the above-identified patent, in accordance with 37 C.F.R. § 1.322.

The patentees request correction of the following errors, which were made by the Patent Office:

- (1) In the claims, there are errors that were introduced at the time of publication.
Such corrections follow:

Claim 1, Col. 100, line 53, the term "heterocydic" should be --heterocyclic--.

Claim 11, Col. 101, line 15, the term "heterocydic" should be --heterocyclic--.


Claim 14, Col. 101, line 24, before the term "or" and after the term "NH₂" please insert --, i.e., a space.

Claim 25, Col. 102, line 23, the term "methylimidazolo" should be --methylimidazolyl--.

The Certificate of Correction corrects these errors.

The mistake appearing in the patent are set forth on the Certificate of Correction enclosed herewith, with an additional copy thereof.

Please charge any shortage in the fees, or credit any overpayment to Deposit Account No. 07-1392.


John L. Lemanowicz
Registration No. 37,380
Attorney for Patentee

Dated: *Sept 28, 2007*
GlaxoSmithKline
Corporate Intellectual Property Dept.
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1467
Facsimile: (919) 483-7988

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,933,299

Page 1 of 1

APPLICATION NO. : 10/030,527

ISSUE DATE : 8/23/05

INVENTOR(S) : Cockerill, et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Claim 1, Col. 100, line 53, the term "heterocydic" should be --heterocyclic--.

Claim 11, Col. 101, line 15, the term "heterocydic" should be --heterocyclic--.

Claim 14, Col. 101, line 24, before the term "or" and after the term "NH₂" please insert --, i.e., a space.

Claim 25, Col. 102, line 23, the term "methylimidazolo" should be --methylimidazolyl--.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

John L. Lemanowicz, Reg. No. 37,380

GlaxoSmithKline

Five Moore Drive, PO Box 13398

Research Triangle Park, NC 27709-3398

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.